Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

PET/CT imaging 2 h after injection of [18F]PSMA-1007 can lead to higher staging of prostate cancer than imaging after 1 h

Hvittfeldt, Erland LU orcid ; Bitzén, Ulrika LU ; Minarik, David LU ; Oddstig, Jenny LU ; Olsson, Berit LU and Trägårdh, Elin LU (2023) In European journal of hybrid imaging 7(1).
Abstract

Background: [18F]PSMA-1007 is a prostate specific membrane antigen (PSMA) ligand for positron emission tomography (PET) imaging of prostate cancer. Current guidelines recommend imaging 90–120 min after injection but strong data about optimal timing is lacking. Our aim was to study whether imaging after 1 h and 2 h leads to a different number of detected lesions, with a specific focus on lesions that might lead to a change in treatment. Methods: 195 patients underwent PET with computed tomography imaging 1 and 2 h after injection of [18F]PSMA-1007. Three readers assessed the status of the prostate or prostate bed and suspected metastases. We analyzed the location and number of found metastases to determine N- and... (More)

Background: [18F]PSMA-1007 is a prostate specific membrane antigen (PSMA) ligand for positron emission tomography (PET) imaging of prostate cancer. Current guidelines recommend imaging 90–120 min after injection but strong data about optimal timing is lacking. Our aim was to study whether imaging after 1 h and 2 h leads to a different number of detected lesions, with a specific focus on lesions that might lead to a change in treatment. Methods: 195 patients underwent PET with computed tomography imaging 1 and 2 h after injection of [18F]PSMA-1007. Three readers assessed the status of the prostate or prostate bed and suspected metastases. We analyzed the location and number of found metastases to determine N- and M-stage of patients. We also analyzed standardized uptake values (SUV) in lesions and in normal tissue. Results: Significantly more pelvic lymph nodes and bone metastases were found and higher N- and M-stages were seen after 2 h. In twelve patients (6.1%) two or three readers agreed on a higher N- or M-stage after 2 h. Conversely, in two patients (1.0%), two readers agreed on a higher stage at 1 h. SUVs in suspected malignant lesions and in normal tissues were higher at 2 h, but lower in the blood pool and urinary bladder. Conclusions: Imaging at 2 h after injection of [18F]PSMA-1007 leads to more suspected metastases found than after 1 h, with higher staging in some patients and possible effect on patient treatment.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
PET/CT, Prostate cancer, PSMA, Uptake time, [F]PSMA-1007
in
European journal of hybrid imaging
volume
7
issue
1
article number
9
publisher
Springer
external identifiers
  • pmid:37121920
  • scopus:85157958767
ISSN
2510-3636
DOI
10.1186/s41824-023-00167-4
language
English
LU publication?
yes
id
e24f48a9-86f8-4472-aadc-f3b21599f6fa
date added to LUP
2023-08-10 10:09:01
date last changed
2024-04-20 00:15:51
@article{e24f48a9-86f8-4472-aadc-f3b21599f6fa,
  abstract     = {{<p>Background: [<sup>18</sup>F]PSMA-1007 is a prostate specific membrane antigen (PSMA) ligand for positron emission tomography (PET) imaging of prostate cancer. Current guidelines recommend imaging 90–120 min after injection but strong data about optimal timing is lacking. Our aim was to study whether imaging after 1 h and 2 h leads to a different number of detected lesions, with a specific focus on lesions that might lead to a change in treatment. Methods: 195 patients underwent PET with computed tomography imaging 1 and 2 h after injection of [<sup>18</sup>F]PSMA-1007. Three readers assessed the status of the prostate or prostate bed and suspected metastases. We analyzed the location and number of found metastases to determine N- and M-stage of patients. We also analyzed standardized uptake values (SUV) in lesions and in normal tissue. Results: Significantly more pelvic lymph nodes and bone metastases were found and higher N- and M-stages were seen after 2 h. In twelve patients (6.1%) two or three readers agreed on a higher N- or M-stage after 2 h. Conversely, in two patients (1.0%), two readers agreed on a higher stage at 1 h. SUVs in suspected malignant lesions and in normal tissues were higher at 2 h, but lower in the blood pool and urinary bladder. Conclusions: Imaging at 2 h after injection of [<sup>18</sup>F]PSMA-1007 leads to more suspected metastases found than after 1 h, with higher staging in some patients and possible effect on patient treatment.</p>}},
  author       = {{Hvittfeldt, Erland and Bitzén, Ulrika and Minarik, David and Oddstig, Jenny and Olsson, Berit and Trägårdh, Elin}},
  issn         = {{2510-3636}},
  keywords     = {{PET/CT; Prostate cancer; PSMA; Uptake time; [F]PSMA-1007}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Springer}},
  series       = {{European journal of hybrid imaging}},
  title        = {{PET/CT imaging 2 h after injection of [<sup>18</sup>F]PSMA-1007 can lead to higher staging of prostate cancer than imaging after 1 h}},
  url          = {{http://dx.doi.org/10.1186/s41824-023-00167-4}},
  doi          = {{10.1186/s41824-023-00167-4}},
  volume       = {{7}},
  year         = {{2023}},
}